Evidence map›Paper›PMID 38854394›Full record

ArticleOpen forum infectious diseases2024

Shared Vision for Improving Outcomes for Serious Fungal Diseases: Report of a Patient, Caregiver, and Clinician Summit.

Rob Purdie, Lisa A Tushla, Jonathan Ferretti, Gonzalo Kiko Castro, Ricky Watson, Thomas Davis, Brianna Raborg, Patrick B Mazi, Angela Stroman, Carolynn Thomas Jones and 5 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rob PurdieIntegrita Healthcare Education Foundation/MyCare, Colorado Springs, Colorado, USA.ORCID https://orcid.org/0009-0009-0787-6578
Lisa A TushlaIntegrita Healthcare Education Foundation/MyCare, Colorado Springs, Colorado, USA.
Jonathan FerrettiIntegrita Healthcare Education Foundation/MyCare, Colorado Springs, Colorado, USA.
Gonzalo Kiko CastroIntegrita Healthcare Education Foundation/MyCare, Colorado Springs, Colorado, USA.
Ricky WatsonIntegrita Healthcare Education Foundation/MyCare, Colorado Springs, Colorado, USA.
Thomas DavisIntegrita Healthcare Education Foundation/MyCare, Colorado Springs, Colorado, USA.
Brianna RaborgIntegrita Healthcare Education Foundation/MyCare, Colorado Springs, Colorado, USA.
Patrick B MaziIntegrita Healthcare Education Foundation/MyCare, Colorado Springs, Colorado, USA.ORCID https://orcid.org/0000-0003-4123-0518
Angela StromanInfectious Diseases Translational Research Unit, Augusta University, Augusta, Georgia, USA.
Carolynn Thomas JonesCollege of Nursing, The Ohio State University, Columbus, Ohio, USA.
Thomas J WalshCenter for Innovative Therapeutics and Diagnostics, Richmond, Virginia.
Tom M ChillerMycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-2251-8033
Peter G PappasMycoses Study Group Education and Research Consortium, Birmingham, Alabama, USA.ORCID https://orcid.org/0000-0002-7219-8242
John MeyerIntegrita Healthcare Education Foundation/MyCare, Colorado Springs, Colorado, USA.
Andrej SpecIntegrita Healthcare Education Foundation/MyCare, Colorado Springs, Colorado, USA.ORCID https://orcid.org/0000-0001-7612-4710

Funding

World Health Organization 001
6 · The paper itself

Abstract

Background: Recently, increasing focus on patient input into research and healthcare improvements has fostered expanded patient-centered advocacy efforts. This first pan-fungal disease summit, part of the MYCology Advocacy, Research, & Education effort, brought together patients, caregivers, and mycology experts to better document patient experiences with invasive fungal disease (IFD) and establish priorities for mycology education, advocacy, and research. Methods: Patients who had suffered from IFD, their caregivers, clinicians, industry representatives, government officials, and patient advocacy professionals were invited. Patients and caregivers shared their stories and struggles with IFD. Breakout sessions separated mycology experts from patients and caregivers for further discussions to identify commonalities and perceived gaps and to formulate recommendations. The 2 groups then reconvened to develop consensus recommendations. Results: IFD patients and their caregivers shared experiences reflecting the typically lengthy prediagnosis, acute treatment, long-term treatment, and posttreatment recovery stages of IFD. They reported substantial physical, psychological, and financial burdens associated with the IFD experience, particularly related to delayed diagnoses. They reaffirmed a need for coordinated patient-centered education, peer support, and advocacy to document the burden of serious fungal infections. Mycology experts discussed strategies to address gaps in the mycology field, such as insufficient training, inadequate workforce support, and a need to partner more with patient groups. Conclusions: A summit involving patients with IFD, family caregivers, and mycology experts identified a substantial nonclinical burden of disease associated with IFD. Patients and mycology experts prioritized several goals for education, advocacy, and research to raise awareness of IFD and improve outcomes.

Indexed as

disease burdenfungal diagnosticsfungal diseasepatient advocacypatient-important outcomes

Identifiers

PMID38854394
PMCPMC11161859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.